Detecting bowel cancer through screening in chronic kidney disease
Wong G, Howard K, Chapman JR, Tong A, Bourke MJ, Hayen A, Macaskill P, Hope RL, Williams N, Kieu A, Allen R, Chadban S, Pollock C, Webster A, Roger SD, Craig JC.Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocol BMC Public Health. 2011 Jun 29;11:516. doi: 10.1186/1471-2458-11-516.
[Free full text]
This is a large-scale, international study of the effects of screening for advanced colorectal neoplasms (advanced adenomas and cancer) using immunochemical faecal occult blood testing (iFOBT) in people with chronic kidney disease (CKD). The DETECT study will provide definitive evidence on the test accuracy of iFOBT screening, the efficiency of early cancer detection, and the barriers/facilitators of implementing a bowel cancer screening program in CKD patients who are at risk of developing and dying from colorectal cancer. Evidence generated from our program of work will inform local and international guidelines and policies on the potential benefits and harms of colorectal cancer screening in individuals with kidney disease.